Pharma giant AstraZeneca to build $2 billion manufacturing facility in Singapore

SINGAPORE – Global biopharmaceutical company AstraZeneca intends to build a US$1.5 billion (S$2 billion) manufacturing facility in Singapore, the company said on May 20.

It aims to begin the designing and construction of the facility by the end of 2024, and targets it to be operationally ready from 2029.

The company’s new facility in Singapore will be designed for manufacturing antibody drug conjugates (ADCs) to enhance the global supply of its ADC portfolio, it said in a statement. ADCs are a form of next-generation treatment that can deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody.